Medical Device | March 16, 2023
Biocorp and HRA Pharma to jointly develop a medical device innovation
Biocorp will receive an initial milestone payment this year
Biocorp will receive an initial milestone payment this year
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Strategic partnership aims to support significant growth of the Ibuprofen product market in Brazil and is backed by Univar Solutions' state-of-the-art Solution Center in São Paulo, Brazil
Investment proposals to the tune of Rs. 54,000 crore has been received in the healthcare and Rs. 17,000 crore has been received in medical education sector
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The new project further expands the partner's long-term collaboration on new technologies for R&D
Subscribe To Our Newsletter & Stay Updated
